[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368213-105":59,"doc-detail-368213-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","breakage-fusion-bridge-cycles-drive-high-oncogene-number-with-moderate-intratumoural-heterogeneity","Breakage fusion bridge cycles drive high oncogene number with moderate intratumoural heterogeneity","","Oncogene amplification drives cancer pathogenesis, and both breakage fusion bridge (BFB) cycles and extrachromosomal DNA (ecDNA) can generate high oncogene copy numbers. The study introduces OM2BFB, an optical genome mapping–based algorithm that detects and reconstructs BFB amplifications with high precision and recall across cell lines, patient-derived xenografts, and primary tumors. Whole-genome sequencing identifies 371 BFB events and shows BFB exhibits distinct heterogeneity and resistance dynamics versus ecDNA.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/breakage-fusion-bridge-cycles-drive-high-oncogene-number-with-moderate-intratumoural-heterogeneity/368213/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/breakage-fusion-bridge-cycles-drive-high-oncogene-number-with-moderate-intratumoural-heterogeneity/368213.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is OM2BFB and what does it detect?","Question",{"text":112,"@type":113},"OM2BFB is an algorithm using optical genome mapping to detect and reconstruct breakage fusion bridge (BFB) amplifications. It evaluates BFB events across multiple cancer model types, including primary tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do BFB and ecDNA differ in oncogene amplification biology?",{"text":117,"@type":113},"BFB and ecDNA are described as distinct oncogene amplification mechanisms with different biological characteristics. Tumors with BFB amplifications show reduced structural heterogeneity in amplicons and delayed resistance onset relative to ecDNA(+) tumors.",{"name":119,"@type":110,"acceptedAnswer":120},"Which cancer types show frequent BFB amplification?",{"text":121,"@type":113},"BFB amplifications are reported as prevalent in cervical, head and neck, lung, and esophageal cancers, while they are rare in brain cancers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368213,1790212909,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Article [https://doi.org/10.1038/s41467-025-56670-8](https://doi.org/10.1038/s41467-025-56670-8)  \nBreakage fusion bridge cycles drive high oncogene number with moderate intratumoural heterogeneity  \nReceived: 27 September 2024  \n\n| Accepted: 24 January 2025 |\n| --- |\n| |\n| Check for updates |\n\nA list of authors and their afﬁliations appears at the end of the paper  \nOncogene ampliﬁcation is a key driver of cancer pathogenesis. Both breakage fusion bridge (BFB) cycles and extrachromosomal DNA (ecDNA) can lead to high oncogene copy numbers, but the impact of BFB ampliﬁcations on intratumoral heterogeneity, treatment response, and patient survival remains poorly understood due to detection challenges with DNA sequencing. We introduce an algorithm, OM2BFB, designed to detect and reconstruct BFBampliﬁcations using optical genome mapping (OGM). OM2BFB demonstrates high precision (>93%) and recall (92%) in identifying BFB ampliﬁcations across cancer cell lines, patient-derived xenograft models, and primary tumors. Comparisons using OGM reveal that BFB detection with our AmpliconSuite toolkit for short-read sequencing also achieves high precision, though with reduced sensitivity. We identify 371 BFB events through whole genome sequencing of 2557 primary tumors and cancer cell lines. BFB ampliﬁcations are prevalent in cervical, head and neck, lung, and esophageal cancers, but rare in brain cancers. Genes ampliﬁed through BFB exhibit lower expression variance, with limited potential for regulatory adaptation compared to ecDNAampliﬁed genes. Tumors with BFB ampliﬁcations (BFB(+)) show reduced structural heterogeneity in amplicons and delayed resistance onset relative toecDNA(+) tumors. These ﬁndings highlight ecDNA and BFB ampliﬁcations as distinct oncogene ampliﬁcation mechanisms with differing biological characteristics, suggesting distinct avenues for therapeutic intervention.  \nSomatic copy number ampliﬁcation of tumour-promoting oncogenesis a major driver of cancer pathogenesis1. High copy ampliﬁcations (CN > 8) are typically localized to speciﬁc genomic regions as focalampliﬁcations (fCNA)2,3. Currently, two main mechanisms for high copy number oncogene ampliﬁcation predominate: extrachromosomal DNA (ecDNA)4,5 and breakage fusion bridge (BFB) cycles6–8. The independent replication of ecDNAs, their random segregation into daughter cells, and the positive selection for a higher (or appropriate) number of proliferative elements (e.g., oncogenes) provides the genetic basis for the rapid modulation of oncogene copy numbers in cells and explains much of the focal oncogene ampliﬁcations observed in cancer4,9. In addition, the circular shape of ecDNAs  \nalter their chromatin accessibility, remodels their physical structure, and interactions of the DNA and its topological domains10–13. Theremodeled structure changes the epigenetic landscape, generates new long-range cis-regulatory interactions, and enhances oncogene transcription to drive tumour pathogenesis. The rapid modulation of DNA copy number mediates resistance to targeted therapy via multiple mechanisms. These include: an increase in the number of copies through selection for higher numbers of ecDNA per cell14, a stabilization in copy number by reintegration of ecDNA into non-native chromosomal locations, or through the biogenesis of entirely new, compensating ecDNA15. Patients whose tumour genomes carry ecDNA are known to have worse outcomes relative to those with ecDNA(-)  \ne-mail: [Jean_Zhao@dfci.harvard.edu](Jean_Zhao@dfci.harvard.edu); [pmischel@stanford.edu](pmischel@stanford.edu); [vbafna@ucsd.edu](vbafna@ucsd.edu)  \nsamples5. For these reasons, identiﬁcation of ecDNA, and vulnerabilities speciﬁc to ecDNA(+) tumours remains an important challenge for understanding cancer biology.  \nThe other main mechanism linked to high copy number oncogene ampliﬁcation in cancer, Breakage-Fusion-Bridge (BFB) cycles, was proposed nearly 80 years ago by Barbara McClintock to explain patterns","cbCairoONInx6cju","https://ap.wps.com/l/cbCairoONInx6cju","pdf",8006016,"English","# Abstract\n## OM2BFB algorithm and performance\n## Genomic mechanisms: BFB vs ecDNA\n## Prevalence across cancer types\n## Impact on heterogeneity and resistance","[{\"question\":\"What is OM2BFB and what does it detect?\",\"answer\":\"OM2BFB is an algorithm using optical genome mapping to detect and reconstruct breakage fusion bridge (BFB) amplifications. It evaluates BFB events across multiple cancer model types, including primary tumors.\"},{\"question\":\"How do BFB and ecDNA differ in oncogene amplification biology?\",\"answer\":\"BFB and ecDNA are described as distinct oncogene amplification mechanisms with different biological characteristics. Tumors with BFB amplifications show reduced structural heterogeneity in amplicons and delayed resistance onset relative to ecDNA(+) tumors.\"},{\"question\":\"Which cancer types show frequent BFB amplification?\",\"answer\":\"BFB amplifications are reported as prevalent in cervical, head and neck, lung, and esophageal cancers, while they are rare in brain cancers.\"}]","Breakage fusion bridge cycles drive high oncogene number with moderate intratumoural heterogeneity | PDF",1790175663,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42ef164cde76d382326d6b20aaf8110a.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9dd5a5fce4936f2636088f26a88c3546.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86e0858a1878607d97ed39bf03e525f9.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/644f99542ae7d6e511987ac46f90b60d.webp",980,1301]